Precision medicine

Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies

Retrieved on: 
Tuesday, August 10, 2021
Janus, IND, Nasdaq, Â, Therapy, PRMT5, Patient, U.S. Securities and Exchange Commission, Probability, Precision medicine, Farallon Capital, Foresite Capital, Barclays, Risk, Cancer, Business, Gilead Sciences, Cooley LLP, PIPE, MTAP, LLC, Guggenheim Partners, SPAC, Population, Acquisition, SEC, GLOBE, Goldman Sachs, MD, SVB Leerink, Pharmaceutical industry, Security (finance)

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango Therapeutics” or “Tango”), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the completion of its business combination with BCTG Acquisition Corp. (Nasdaq: BCTG), a special purpose acquisition company (SPAC) sponsored by Boxer Capital. Tango Therapeutics, Inc., the resulting combined company, will commence trading on the Nasdaq Capital Market under the symbol “TNGX” on August 11, 2021. Tango will have a total cash position of approximately $515 million after transactions costs, which includes approximately $342 million from BCTG’s trust account and the private investment in public equity (PIPE) financing expected to fund later today. BCTG’s shareholders approved the transaction on August 9, 2021. The transaction was previously approved by Tango Therapeutics’ shareholders. Tango Therapeutics’ management team will continue to be led by Barbara Weber, MD, President and Chief Executive Officer.

Key Points: 
  • Tango Therapeutics, Inc., the resulting combined company, will commence trading on the Nasdaq Capital Market under the symbol TNGX on August 11, 2021.
  • Tango Therapeutics management team will continue to be led by Barbara Weber, MD, President and Chief Executive Officer.
  • Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
  • However, while Tango may elect to update these forward-looking statements at some point in the future, Tango specifically disclaims any obligation to do so.

Tesis Labs and Personal Genome Diagnostics Announce Collaboration to Advance Cancer Profiling and Treatment

Retrieved on: 
Tuesday, August 10, 2021
Oncology, Health, Genetics, Other Science, Science, Pharmaceutical, Biotechnology, Adoption, Creativity, Genetic testing, Degenerative disease, Johns Hopkins University, National, Diabetes, Patient, Genomics, Physician, Hospital, Precision medicine, Medicine, Solution, Cancer, NGS, Conditional sentence, Research, Plasma, Genome, Data analysis, FDA, Death, Laboratory, Tesis, Biomarker, Liquid biopsy, Antibiotics, Pharmaceutical industry, Medical imaging, Tesis Labs, Personal Genome Diagnostics, TESIS LABS, PERSONAL GENOME DIAGNOSTICS

Tesis Labs , a leader in targeted genetic sequencing, and Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a new collaboration to maximize the power of genetic sequencing and bioinformatics.

Key Points: 
  • Tesis Labs , a leader in targeted genetic sequencing, and Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a new collaboration to maximize the power of genetic sequencing and bioinformatics.
  • This new strategic collaboration brings together highly specialized clinical laboratory and biotechnology teams, enabling their expertise, creativity, and passion for delivering the latest genetic and bioinformatic insights to advance cancer predisposition, profiling, and treatment.
  • Our clinical expertise and approaches to unlocking the power of genetic sequencing are bringing new insights to cancer research, profiling and treatment.
  • Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome.

VERAXA Biotech and Indivumed Cooperate on the Development of Precision Oncology Antibody Drugs

Retrieved on: 
Tuesday, August 10, 2021
Intelligence, EMBL, European Molecular Biology Laboratory, Therapy, Top of the Form (quiz show), CEO, G protein-coupled receptor, Precision medicine, Antibody, Human, Technology, Time, Cancer, European, Colorectal cancer, Research, Mouse, Mab, Ion, Disease, Fine chemical, Medical device

The antibody development and commercialization will be performed by Indivumed's subsidiary, Ix Therapeutics.

Key Points: 
  • The antibody development and commercialization will be performed by Indivumed's subsidiary, Ix Therapeutics.
  • VERAXA Biotech GmbH is a pioneer in microfluidic technology for the screening of antibodies with modulatory function on complex signal proteins like GPCRs or ion channels.
  • Besides carrying out service projects, VERAXA is currently also establishing its own proprietary pipeline of therapeutic antibody candidates for further joint development with pharma partners.
  • Ix Therapeutics is a subsidiary of Indivumed that was founded in 2021 to develop therapeutic antibodies based on novel and proprietary targets of Indivumed.

Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors

Retrieved on: 
Tuesday, August 10, 2021
Diamond, MAP, Private Securities Litigation Reform Act, Precision medicine, IND, Gilead Sciences, Patient, FDA, COVID-19, IPO, LLS, M26 Modular Accessory Shotgun System, Cancer, CGI, Washington University in St. Louis, Nasdaq, U.S. Securities and Exchange Commission, Leukemia, Leadership, Black Diamond, Corporation, Growth, Senior advisor, Senior, Form 10-K, NEW, GLOBE, Annual report, Yale New Haven Hospital, Norwest Venture Partners, G1 Therapeutics, Board, Company, Gilead, Board of directors, Series, Faculty, Yale University, Therapy, Pharmaceutical industry, Management

and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M.D., Ph.D. to its Board of Directors.

Key Points: 
  • and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M.D., Ph.D. to its Board of Directors.
  • I am delighted to welcome Mark to the Black Diamond Board of Directors, said Robert A. Ingram, Chairman of the Board of Directors of Black Diamond Therapeutics.
  • We are pleased to welcome Mark to our Board, as his financial, regulatory, and medical expertise will complement our existing credentialed group of directors, said David M. Epstein, Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics.
  • I am delighted to join Black Diamond Therapeutics Board of Directors, as their novel approach to precision medicine has the potential to transform the treatment landscape of targeted therapies.

Goldfinch Bio Announces Initiation of Open-Label Extension Study for Patients with Focal Segmental Glomerular Sclerosis (FSGS) Enrolled in Phase 2 Clinical Trial of GFB-887

Retrieved on: 
Tuesday, August 10, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, FASN, Precision medicine, Dialysis, Patient, Hope, Week, Quality of life, Clinical trial, Podocyte, Providence Healthcare, FSGS, Kidney, Kidney disease, Proteinuria, Transplant, Safety, PK, Transience, Diabetic nephropathy, DN, Biomarker, Time, University of Washington Medical Center, Microfilament, PD, FACP, Bio, University, Glomerulosclerosis, Pharmacokinetics, Research, TRPC5, Pharmaceutical industry, TRACTION-2 and the Open-Label Extension Study, GFB-887, Goldfinch Bio, TRACTION-2 AND THE OPEN-LABEL EXTENSION STUDY, GFB-887, GOLDFINCH BIO

Anticipated to enroll approximately 35 patients, the extension study is designed to evaluate the long-term safety and tolerability of GFB-887.

Key Points: 
  • Anticipated to enroll approximately 35 patients, the extension study is designed to evaluate the long-term safety and tolerability of GFB-887.
  • Were grateful to the TRACTION-2 and extension study investigators, clinical research staff and, most importantly, the patients who are participating in these important studies.
  • FSGS patients in the open-label extension study will be enrolled from the ongoing Phase 2 TRACTION-2 multiple ascending dose trial.
  • 1 Patients diagnosed with treatment-resistant minimal change disease (TR-MCD) which is considered a subset of FSGS, are also being enrolled in the Phase 2 open label extension study.

QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements

Retrieved on: 
Monday, August 9, 2021
Software, Biotechnology, Pharmaceutical, Oncology, Health, Technology, Genetics, Other Technology, Fallopian tube cancer, Blood, Automation, Cdx, Fast Track, Adoption, IVD, Squamous cell carcinoma, Precision medicine, Polymerase chain reaction, Colorectal cancer, Bevacizumab, COVID-19, FDA, TME, CEO, Lists of diseases, Regulation of tobacco by the U.S. Food and Drug Administration, Breast cancer, QGEN, EGFR, List of life sciences, Tumor microenvironment, PCR, Cancer, Life, KRAS, DNA, Growth, Solution, Patient, NYSE, Budget, Transport, BRAF, PIK3CA, Lists of disasters, Marketing, Large-cell lung carcinoma, Weather, RNA, Food, NGS, Research, U.S. Securities and Exchange Commission, Protein, Biotechnology, Knowledge, FGFR, Ovarian cancer, Decision-making, Annual report, Molecular diagnostics, Vaccine, Medical imaging, Pharmaceutical industry, OncXerna Therapeutics, its Xerna™ RNA-based Biomarker Platform, and Xerna™ TME Panel, QIAGEN, ONCXERNA THERAPEUTICS, ITS XERNA™ RNA-BASED BIOMARKER PLATFORM, AND XERNA™ TME PANEL, QIAGEN

QIAGEN and OncXerna have agreed to collaborate to advance the Xerna TME panel towards IVD (in-vitro diagnostic) regulatory approval as a NGS companion diagnostic for Navicixizumab, which is being developed by OncXerna as a treatment for patients with ovarian cancer.

Key Points: 
  • QIAGEN and OncXerna have agreed to collaborate to advance the Xerna TME panel towards IVD (in-vitro diagnostic) regulatory approval as a NGS companion diagnostic for Navicixizumab, which is being developed by OncXerna as a treatment for patients with ovarian cancer.
  • We are very pleased to complete these agreements with QIAGEN, which we see as providing important external validation for the Xerna TME panel and our broader RNA-based biomarker platform, stated Dr. Laura Benjamin, OncXerna Founder and CEO.
  • QIAGEN has an unmatched depth and breadth of technologies from next-generation sequencing (NGS) to polymerase chain reaction (PCR) for companion diagnostic development.
  • Currently, QIAGEN is working under master collaboration agreements with more than 25 companies to develop and commercialize companion diagnostic tests for their drug candidates a deep pipeline of potential future products to advance Precision Medicine for the benefit of patients.

Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, August 9, 2021
Science, Health, Oncology, Research, Technology, Drug discovery, Society, DDR, Precision medicine, COVID-19, Sale, FDA, American Society of Clinical Oncology, EDGAR, Therapy, Fred Hutchinson Cancer Research Center, Cancer, Annual general meeting, DNA repair, DNA, Patient, Investigational New Drug, SEC, Homologous recombination, Prospectus, ASCO, Forward-looking statement, Intention, Safety, Marketing, Exercise, G&A, IND, IPO, U.S. Securities and Exchange Commission, R, Research, Pharmaceutical industry

Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent business highlights.

Key Points: 
  • Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent business highlights.
  • Cash and cash equivalents: Cash and cash equivalents for the quarter ended June 30, 2021, were $198.6 million.
  • Research and development (R&D) expenses: R&D expenses were $8.9 million for the second quarter of 2021 versus $3.6 million for the same period in 2020.
  • Net loss: Net loss was $11.3 million, or $4.83 per share in the second quarter of 2021 compared to $4.5 million, or $3.18 per share in the second quarter of 2020.

FDB Launches Clinical Decision Support Analytics Solution

Retrieved on: 
Monday, August 9, 2021
MHK, Precision medicine, Patient safety, CDS, ROI, Population Health Management, ECRI Institute, SAN, Health, Community Hospital East, MD, Hearst, Partnership, EHR, Exhibition, Multimedia, Organization, Pharmacy, Solution, Patient, Abrazo Community Health Network, LinkedIn, MCG, FDB, Conference, First Databank, View, Safety, Prescription, YouTube, Education, Hospital, Twitter, Physician, Pharmaceutical industry, Computer data storage, Medicine

"Community Health Network is excited to build a deeper partnership with FDB as an early adopter of FDB CDS Analytics," said Patrick McGill, MD, Chief Analytics Officer, Community Health Network.

Key Points: 
  • "Community Health Network is excited to build a deeper partnership with FDB as an early adopter of FDB CDS Analytics," said Patrick McGill, MD, Chief Analytics Officer, Community Health Network.
  • With FDB CDS Analytics, we gain a more thorough view of which clinical decision support is effective and which CDS rules are not working as intended, which enables us to identify opportunities for improved clinical decision support.
  • PatientFirst Care Guidance also includes FDB AlertSpace , FDB Targeted Medication Warnings and FDB's pharmacogenomic clinical decision support .
  • "FDB has been, and continues to be, the leading provider of medication decision support with unmatched clinical expertise and experience," Katter said.

Cohen Veterans Bioscience, Stanford Brain Performance Center, and Brain Trauma Foundation Join Forces to Advance Precision Medicine for TBI

Retrieved on: 
Monday, August 9, 2021
CVB, Technology, Accident, FACS, Adoption, Population, Guideline, Precision medicine, Foundation, CEO, BTF, Trauma, Traumatic brain injury, Concussion, Health, Neuroscience, Brain Trauma Foundation, TBI, Industry, Biomedical Research, Government, Science, Data science, Classification, Death, Partnership, Emergency medicine, Sport, Associate, Organization, Solution, Patient, Stanford University School of Medicine, Ageing, Step, Research, Therapy, Stanford University, Prevalence, Neurosurgery, Medicine, Medical device, Medical imaging

"The Stanford Brain Performance Center and the Brain Trauma Foundation have advanced our understanding of best practices for traumatic brain injury.

Key Points: 
  • "The Stanford Brain Performance Center and the Brain Trauma Foundation have advanced our understanding of best practices for traumatic brain injury.
  • The Stanford Brain Performance Center is an interdisciplinary center in the Stanford school of medicine.
  • Founded in 1986 by Dr. Ghajar, the Brain Trauma Foundation was created to improve outcome from TBI.
  • The Brain Trauma Blueprint is a framework to advance precision diagnostics and therapeutics for brain trauma through a process of community stakeholder consensus roadmapping and collaborative execution.

Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States

Technology, Longevity, United, Adoption, Leadership, Precision medicine, Health, GLOBE, SVP, GRAIL, COVID-19, ANTM, Degenerative disease, Whole genome sequencing, Genomics, Antibody, Patient, NASDAQ, NYSE, AI, AMGN, Amgen, Research, Partnership, Blue Shield, Medical imaging, Antibiotics

CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Mark Morgan as a board member.

Key Points: 
  • CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Mark Morgan as a board member.
  • Mark is the SVP of Market Access for GRAIL, which has developed a highly innovative multi-cancer, early detection blood test.
  • We are excited to welcome Mark Morgan to the Dante Labs Board, said Dante Labs CEO Andrea Riposati, Mark is a rockstar in healthcare.
  • Mr. Morgan will join Illumina (NASDAQ:ILMN) Chief Operations Officer Bob Ragusa to Dante Labs Board of Directors.